NZ708959A - Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same - Google Patents
Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the sameInfo
- Publication number
- NZ708959A NZ708959A NZ70895913A NZ70895913A NZ708959A NZ 708959 A NZ708959 A NZ 708959A NZ 70895913 A NZ70895913 A NZ 70895913A NZ 70895913 A NZ70895913 A NZ 70895913A NZ 708959 A NZ708959 A NZ 708959A
- Authority
- NZ
- New Zealand
- Prior art keywords
- propyl
- diisobutylamino
- piperazin
- imidazol
- benzo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12306690 | 2012-12-27 | ||
| PCT/EP2013/078068 WO2014102339A1 (en) | 2012-12-27 | 2013-12-27 | Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ708959A true NZ708959A (en) | 2019-11-29 |
Family
ID=47501005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ70895913A NZ708959A (en) | 2012-12-27 | 2013-12-27 | Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US9562018B2 (enExample) |
| EP (1) | EP2938597B1 (enExample) |
| JP (1) | JP6384923B2 (enExample) |
| KR (1) | KR102115060B1 (enExample) |
| CN (1) | CN105008333B (enExample) |
| AU (2) | AU2013369288B2 (enExample) |
| BR (1) | BR112015015474B1 (enExample) |
| CA (1) | CA2895285C (enExample) |
| DK (1) | DK2938597T3 (enExample) |
| ES (1) | ES2605494T3 (enExample) |
| HR (1) | HRP20161612T2 (enExample) |
| HU (1) | HUE030930T2 (enExample) |
| IL (1) | IL239450B (enExample) |
| LT (1) | LT2938597T (enExample) |
| MX (1) | MX363367B (enExample) |
| NZ (1) | NZ708959A (enExample) |
| PL (1) | PL2938597T3 (enExample) |
| PT (1) | PT2938597T (enExample) |
| RS (1) | RS55511B1 (enExample) |
| RU (1) | RU2655454C2 (enExample) |
| SI (1) | SI2938597T1 (enExample) |
| WO (1) | WO2014102339A1 (enExample) |
| ZA (1) | ZA201504521B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2605494T3 (es) | 2012-12-27 | 2017-03-14 | Alzprotect | Sales de sulfato de N-(3-(4-(3-(diisobutilamino)propil)piperazin-1-il)propil)-1H-benzo[d]imidazol-2-amina, preparación y uso de las mismas |
| ES2715960T3 (es) | 2015-03-16 | 2019-06-07 | Inst Nat Sante Rech Med | Nuevo derivado de 1,4-bis(3-aminopropil)piperazina y su uso |
| TWI744300B (zh) * | 2016-03-23 | 2021-11-01 | 里爾中央醫學中心 | 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途 |
| IL301559A (en) * | 2020-10-01 | 2023-05-01 | Alzprotect | Succinate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[D]imidazol-2-amine, their preparation and use |
| ES3019615T3 (en) * | 2020-10-07 | 2025-05-20 | Alzprotect | Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine sulphate salts and solvates thereof for the treatment of motor neuron diseases and neuromuscular junction disorders |
| US20250041290A1 (en) | 2021-12-20 | 2025-02-06 | Alzprotect | USE OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[d]IMIDAZOL-2-AMINE SUCCINATE SALTS AND SOLVATES THEREOF FOR THE TREATMENT OF MOTOR NEURON DISEASES AND NEUROMUSCULAR JUNCTION DISORDERS |
| EP4499091A1 (en) | 2022-03-25 | 2025-02-05 | Alzprotect | Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine salts and solvates thereof for the treatment of sensory neuron diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2674856B1 (fr) * | 1991-04-05 | 1993-07-30 | Esteve Labor Dr | Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments. |
| AU739998B2 (en) * | 1997-06-12 | 2001-10-25 | Transgene S.A. | Novel lipid complexes for transferring at least one therapeutically active substance, in particular a polynucleotide, into a target cell, and use in gene therapy |
| WO2000018767A2 (en) | 1998-09-30 | 2000-04-06 | Neurogen Corporation | 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands |
| WO2002096431A1 (en) * | 2001-05-25 | 2002-12-05 | The Regents Of The University Of California | Optically active compounds clearing malformed proteins |
| US20040116441A1 (en) * | 2002-10-30 | 2004-06-17 | Pfizer Inc | Methods of using sulfonic acid derivatives |
| JP4660199B2 (ja) * | 2002-12-23 | 2011-03-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換１−ピペリジン−４−イル−４−アゼチジン−３−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用 |
| ATE524181T1 (de) * | 2004-11-10 | 2011-09-15 | Inst Nat Sante Rech Med | Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen |
| ES2605494T3 (es) * | 2012-12-27 | 2017-03-14 | Alzprotect | Sales de sulfato de N-(3-(4-(3-(diisobutilamino)propil)piperazin-1-il)propil)-1H-benzo[d]imidazol-2-amina, preparación y uso de las mismas |
-
2013
- 2013-12-27 ES ES13815780.5T patent/ES2605494T3/es active Active
- 2013-12-27 US US14/655,642 patent/US9562018B2/en active Active
- 2013-12-27 PT PT138157805T patent/PT2938597T/pt unknown
- 2013-12-27 WO PCT/EP2013/078068 patent/WO2014102339A1/en not_active Ceased
- 2013-12-27 EP EP13815780.5A patent/EP2938597B1/en active Active
- 2013-12-27 HU HUE13815780A patent/HUE030930T2/hu unknown
- 2013-12-27 PL PL13815780T patent/PL2938597T3/pl unknown
- 2013-12-27 MX MX2015008502A patent/MX363367B/es unknown
- 2013-12-27 JP JP2015550088A patent/JP6384923B2/ja active Active
- 2013-12-27 RU RU2015130671A patent/RU2655454C2/ru active
- 2013-12-27 CA CA2895285A patent/CA2895285C/en active Active
- 2013-12-27 NZ NZ70895913A patent/NZ708959A/en unknown
- 2013-12-27 BR BR112015015474-3A patent/BR112015015474B1/pt active IP Right Grant
- 2013-12-27 RS RS20161055A patent/RS55511B1/sr unknown
- 2013-12-27 CN CN201380068524.8A patent/CN105008333B/zh active Active
- 2013-12-27 HR HRP20161612TT patent/HRP20161612T2/hr unknown
- 2013-12-27 SI SI201330408A patent/SI2938597T1/sl unknown
- 2013-12-27 KR KR1020157017192A patent/KR102115060B1/ko active Active
- 2013-12-27 LT LTEP13815780.5T patent/LT2938597T/lt unknown
- 2013-12-27 AU AU2013369288A patent/AU2013369288B2/en active Active
- 2013-12-27 DK DK13815780.5T patent/DK2938597T3/en active
-
2015
- 2015-06-16 IL IL239450A patent/IL239450B/en active IP Right Grant
- 2015-06-23 ZA ZA2015/04521A patent/ZA201504521B/en unknown
-
2016
- 2016-12-22 US US15/388,349 patent/US10537569B2/en active Active
-
2018
- 2018-03-28 AU AU2018202218A patent/AU2018202218B2/en active Active
-
2019
- 2019-08-27 US US16/552,436 patent/US10772884B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN01156A (enExample) | ||
| PH12015500983A1 (en) | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections | |
| MX2015008502A (es) | Sales sulfato de n-(3-(4-(3-(diisobutilamino)propil)piperazin-1-il )propil)-1h-benzo [d]imidazol-2-amina, preparación y uso de las mismas. | |
| WO2014028591A3 (en) | N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| UA115558C2 (uk) | Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань | |
| MX2013004307A (es) | Derivados de arilamida como bloqueadores de ttx-s. | |
| PH12013502156A1 (en) | 1,3-oxazines as bace1 and/or bace2 inhibitors | |
| PH12013502316A1 (en) | Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors | |
| IN2012DN01233A (enExample) | ||
| PH12013502262A1 (en) | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors | |
| MX2013007558A (es) | 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2). | |
| MY175854A (en) | Novel quinolone derivatives | |
| MX2013007957A (es) | 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2). | |
| PH12015500713A1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| MX2013004759A (es) | Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl). | |
| PH12015501609A1 (en) | Phenicol antibacterials | |
| PH12014501334A1 (en) | Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines | |
| MX2013014194A (es) | 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2). | |
| PH12015502365A1 (en) | Bace1 inhibitors | |
| MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
| PH12014502541A1 (en) | 5-amino [1,4] thiazines as bace 1 inhibitors | |
| IL216149A (en) | Heterocyclic phenoxymethyl compounds, their pharmaceutical preparations and their use in the preparation of drugs for the treatment of central nervous system disorders | |
| UA117154C2 (uk) | Антагоністи s1p3 | |
| IN2015DN02109A (enExample) | ||
| IL220698A (en) | Annotation (s) –n– (4– (4– acetylpiperazine – 1 – ram) benzyl) - n– (1– (4 – benzylpiperazine – 1 – ram) –1 – oxo-3-phenyl-propane-2-ram ) Acrylamide, containing and using pharmaceutical preparations for the preparation of medicines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: ALZPROTECT PARC EURASANTA - LE GALENIS, FR Effective date: 20191029 Owner name: UNIVERSITE DE LILLE, FR Effective date: 20191029 Owner name: INSERM (INSTITUT NATIONAL DE LA SANTA ET DE L, FR Effective date: 20191029 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2021 BY ACUMASS Effective date: 20201118 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2022 BY ACUMASS Effective date: 20211122 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2023 BY ACUMASS Effective date: 20221118 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2024 BY ACUMASS Effective date: 20231121 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2025 BY OLIVIER BARLOY Effective date: 20241120 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 DEC 2026 BY ACUMASS Effective date: 20251120 |